Each year, more human pluripotent stem cell(hPSC)-derived therapies move toward the clinic, which is why it’s important to stay up-to-date with the latest advancements in the field. Whether you’re just about to start your next project or are well on your way to clinical trials, the big picture of clinical translation in terms of patient safety, cell quality, and physiological relevance should always be top of mind.
Below is a collection of scientific resources to highlight the exciting potential of hPSC-derived therapies.
In this Innovation Showcase presentation, Lynn Csontos demonstrates how STEMCELL can support your project timing, product quality, and overall vision by building quality into our products, processes, and policies. Kimberly Snyder then presents data showing how TeSR™-AOF, a novel animal origin-free (AOF) hPSC maintenance medium, supports optimized cell quality, improved performance, and reproducibility across all cell lines.
StemCell Technologies Inc. and affiliates ("STEMCELL Technologies") does not
share your email address with third parties. StemCell Technologies Inc. will use your email address to
confirm your identity and send you newsletters, transaction-related emails, promotional and customer
your email preferences at any time.